Pipeline
Our Pipeline is comprised of Biologics, including the proprietary BEAT® MultispecificsTM platform, and one Cbl-b inhibitor small molecule, targeting the spectrum of immune cell engagement and indications across hematologic and solid tumors. If you are interested in exploring a partnership, Contact us.
Diversity of Immune Cell Engagement in Autoimmune Diseases and Across Hematologic & Solid Tumor Indications
| ASSETS | DESCRIPTION | INDICATION |
|---|---|---|
| DISCOVERY | PRECLINICAL | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| RIGHTS |
|---|
(ABBV-2001)
*
(ISB 830)
ISB 830-X8
(STAR-0310)
*IGI will partner with Glenmark to develop, manufacture, and commercialize ISB 2001/ABBV-2001 in all territories outside AbbVie’s licensed markets
Oncology
Immunology
PRODUCTS
ASSETS
DESCRIPTION
CD38 x BCMA x CD3 Trispecific
INDICATION
Multiple Myeloma
PHASE
RIGHTS
*
PRODUCTS
ASSETS
ISB 880 (ALM27134)
DESCRIPTION
IL-1RAP antagonist mAb
INDICATION
Hidradenitis Suppurativa
PHASE
RIGHTS
PRODUCTS
ASSETS
Telazorlimab (ISB 830)
DESCRIPTION
OX40 antagonist mAb
INDICATION
Atopic Dermatitis
PHASE
RIGHTS
PRODUCTS
ASSETS
ISB 830-X8 (STAR-0310)
DESCRIPTION
OX40 antagonist mAb
INDICATION
Atopic Dermatitis
PHASE
RIGHTS
PRODUCTS
ASSETS
ISB 2301
DESCRIPTION
IMMUNITE™ multimodal immunotherapy
INDICATION
Solid Tumors
PHASE
RIGHTS
PRODUCTS
ASSETS
DESCRIPTION
Cbl-b Inhibitor
INDICATION
Solid Tumors
PHASE
RIGHTS